X0306 4 2016-10-31 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001297709 Novartis Bioventures Ltd C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 SWITZERLAND 0 0 1 0 0001114448 NOVARTIS AG LICHTSTRASSE 35 BASEL V8 CH 4056 SWITZERLAND 0 0 1 0 Common Stock 2016-10-31 4 X 0 62914 0.07 A 62914 D Common Stock 2016-10-31 4 S 0 339 13.00 D 62575 D Common Stock 2016-10-31 4 C 0 1389797 A 1452372 D Common Stock 2016-10-31 4 C 0 522561 A 1974933 D Common Stock 2016-10-31 4 C 0 486104 A 2461037 D Common Stock 2016-10-31 4 P 0 84615 13.00 A 2545652 D Warrants to Purchase Common Stock 0.07 2016-10-31 4 X 0 62914 D 2022-04-01 Common Stock 62914 0 D Series A Preferred Stock 2016-10-31 4 C 0 9728589 D Common Stock 1389797 0 D Series B-1 Preferred Stock 2016-10-31 4 C 0 3657932 D Common Stock 522561 0 D Series B-2 Preferred Stock 2016-10-31 4 C 0 3402729 D Common Stock 486104 0 D The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG. The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 339 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 62,575 shares, after deducting the aggregate exercise price. Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. /s/ Simon Zivi, Authorized Signatory /s/ Laurieann Chaikowsky, Authorized Signatory 2016-10-31 /s/ Simon Zivi, Chairman /s/ Laurieann Chaikowsky, Authorized Signatory 2016-10-31